U.S. Physical Therapy Reports Strong 2025 Results, Raises Dividend, and Issues Positive 2026 Guidance Amidst CFO Transition

summarizeSummary

U.S. Physical Therapy reported strong Q4 and full-year 2025 operational results, including significant revenue and Adjusted EBITDA growth, and provided optimistic 2026 Adjusted EBITDA guidance. The company also announced a new strategic hospital alliance, recent acquisitions, a dividend increase, and a CFO transition.

check_boxKey Events

• Strong 2025 Financial Performance

  U.S. Physical Therapy reported a 16.2% increase in full-year Adjusted EBITDA to $95.0 million and 13.0% growth in Q4 physical therapy revenue. Full-year GAAP Net Income was $39.6 million, though EPS declined to $1.42 due to non-cash revaluations of redeemable noncontrolling interests.

• Positive 2026 Adjusted EBITDA Guidance

  The company issued Adjusted EBITDA guidance for 2026 in the range of $102.0 million to $106.0 million, indicating continued growth from the $95.0 million reported in 2025.

• New Strategic Hospital Alliance Announced

  A new 10-year strategic alliance was announced with a local hospital system, involving 10 existing outpatient physical therapy clinics. This alliance is expected to contribute at least $1.3 million in incremental annualized EBITDA to U.S. Physical Therapy.

• CFO Transition

  Carey Hendrickson resigned as Chief Financial Officer, effective April 24, 2026, to pursue another CFO position. Jason Curtis, Senior Vice President of Finance and Accounting, will assume the role of interim CFO.

auto_awesomeAnalysis

This 8-K filing provides a comprehensive update, highlighting U.S. Physical Therapy's robust operational performance in 2025, with significant increases in Adjusted EBITDA and physical therapy revenue. While GAAP net income and EPS declined due to non-cash revaluations of noncontrolling interests and contingent earnouts, the underlying business momentum is strong. The company's positive 2026 Adjusted EBITDA guidance, projecting a notable increase from 2025, offers a strong forward-looking signal of continued growth. The announcement of a new strategic hospital alliance, alongside recent acquisitions, underscores the company's expansion strategy and is expected to contribute substantially to future EBITDA. The dividend increase and share repurchase further signal management's confidence in the company's financial health. The CFO's resignation, while a notable event, is mitigated by the stated amicable nature of the departure and the appointment of an experienced interim successor. Investors should focus on the strong operational momentum and growth initiatives, which are expected to drive future value.